Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and D-methamphetamine in healthy volunteers: A double-blind, placebo-controlled PET study with [18F]FDG

Neuropsychopharmacology

Volumn 20, Issue 6, 1999, Pages 565-581

  Gouzoulis Mayfrank, Euphrosyne ^a   Schreckenberger, Mathias ^a,b   Sabri, Osama ^a   Arning, Christoph ^a   Thelen, Bernhard ^a   Spitzer, Manfred ^a,b   Kovar, Karl Artur ^c   Hermle, Leopold ^c   Büll, Udalrich ^a   Sass, Henning ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Activation study; Ecstasy; FDG PET; MDE; Methamphetamine; Model psychosis; Psilocybin

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; METHAMPHETAMINE; PSILOCYBINE;

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CEREBELLUM; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMPARISON; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; HYPERMETABOLISM; MALE; NEOCORTEX; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THALAMUS;

3,4-METHYLENEDIOXYAMPHETAMINE; ADRENERGIC AGENTS; ADULT; CEREBELLUM; COGNITION; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; HALLUCINOGENS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHAMPHETAMINE; MIDDLE AGED; NOOTROPIC AGENTS; PSILOCYBINE; PSYCHOPATHOLOGY;

EID: 0033151455     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00089-X     Document Type: Article

References (88)

1. Akshoomoff N.A., Courchesne E. A new role for the cerebellum in cognitive operations. Behav Neurosci. 106:1992;731-738.
2. Allen G., Buxton R.B., Wong E.C., Courchesne E. Attentional activation of the cerebellum independent of motor involvement. Science. 275:1997;1940-1943.
3. Andreasen N.C., Rezai K., Alliger R., Swayze V.W., Flaum M., Kirchner P., Cohen G., O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with Xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiat. 49:1992;943-952.
4. Andreasen N.C., O'Leary D.S., Cizadlo T., Arndt S., Rezai K., Boles Ponto L.L., Watkins G.L., Hichwa R.D. Schizophrenia and cognitive dysmetria. A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry Proc Natl Acad Sci. 93:1996;9985-9990.
5. Andreasen N.C. The role of the thalamus in schizophrenia. Can J Psychiat. 42:1997;27-33.
6. Angrist B. Amphetamine psychosis. Clinical variations of the syndrome Cho A.K., Segal D.S. Amphetamine and its analogs. 1994;387-414 Toxicology, and Abuse. San Diego, CA, Academic Press, Pharmacology.
7. Bartlett E.J., Brodie J.D., Wolf A.P., Christman D.R., Laska E., Meissner M. Reproducibility of cerebral glucose metabolic measurements in resting human subjects. J Cereb Blood Flow Metab. 8:1988;502-512.
8. Beaumont J.G., Dimond S.J. Brain disconnection and schizophrenia. Br J Psychiat. 123:1973;661-662.
9. Bech P. Rating scales for mood disorders. Applicability, consistency, and construct validity Acta Psychiat Scand. 78:1988;45-55.
10. Benes F.M., Bird E.D. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiat. 44:1987;608-616.
11. Benes F.M., Majocha R., Bird E.D., Marotta C.A. Increased vertical axon numbers in cingulate cortex of schizophrenics. Arch Gen Psychiat. 44:1987;1017-1021.
12. Bentivoglio M., Kultas-Ilinsky K., Ilinsky I. Limbic thalamus. Structure, intrinsic organization and connections Vogt B.A., Gabriel M. Neurobiology of Cingulate Cortex and Limbic Thalamus. A Comprehensive Handbook:1993;71-122 Birkhäuser, Boston.
13. Bleuler E (1911): Dementia praecox oder Gruppe der Schizophrenien. Leipzig-Wien, Deuticke. Transl. Ziskin J, Lewis ND (1950): Dementia Praecox or the Group of Schizophrenias. New York, Intern. University Press.
14. Buchsbaum M.S., Ingvar D.H., Kessler R., Waters R.N., Cappelletti J., van Kammen D.P., King A.C., Johnson J.J., Manning R.G., Flynn R.M., Mann L.S., Bunney W.E. Jr., Sokoloff L. Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia. Arch Gen Psychiat. 39:1982;251-259.
15. Buchsbaum M.S., Nuechterlein K.H., Haier R.J., Wu J., Sicotte N., Hazlett E., Asarnow R., Potkin S., Guich S. Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br J Psychiat. 156:1990;216-227.
16. Catafau A.M., Parellada E., Lomena F.J., Bernardo M., Pavía J., Ros D., Setoain J., Gonzalez-Monclús E. Prefrontal and temporal blood flow in schizophrenia. Resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease J Nucl Med. 35:1994;935-941.
17. Cleghorn J.M., Garnett E.S., Nahmias C., Firnau G., Brown G.M., Kaplan R., Szechtman H., Szechtman B. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiat Res. 28:1989;119-133.
18. Cleghorn J.M., Franco S., Szechtman B. Toward a brain map of auditory hallucinations. Am J Psychiat. 149:1992;1062-1069.
19. Cohen R.M., Semple W.E., Gross M., Nordahl T.E., DeLisi L.E., Holcomb H.H., King A.C., Morihisa J.M., Pickar D. Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 40:1987;2031-2039.
20. Devinsky O., Morrel M.J., Vogt B.A. Contributions of anterior cingulate cortex to behavior. Brain. 118:1995;279-306.
21. Devous M.D. Sr., Trivedi M.H., Gong W., Harris T.S., Rush A.J. rCBF changes in limbic and limbically innervated brain regions in normal controls following oral amphetamine challenge. J Cereb Blood Flow. 15:1995;S829.
22. 99mTc-Exametazime in unmedicated schizophrenic patients. Biol Psychiat. 33:1993;487-495.
23. Ernst M., Zametkin A.J., Matochik J., Schmidt M., Jons P.H., Liebenhauer L.L., Hardy K.K., Cohen R.M. Intravenous dextroamphetamine and brain glucose metabolism. Neuropsychopharmacology. 17:1997;391-401.
24. Farkas T., Wolf A.P., Jaeger J., Brodie J.D., Christman D.R., Fowler J.S. Regional brain glucose metabolism in chronic schizophrenia. A positron emission transaxial tomographic study. Arch Gen Psychiat. 41:1984;293-300.
25. Gamma A., Buck A., Hell D., Vollenweider F.X. 3,4-methylenedioxymethamphetamine (MDMA) alters the pattern of regional cerebral blood flow (rCBF) in drug-naive volunteers. Pharmacopsychiatry. 30:1997;170.
26. Gao J.-H., Parsons L.M., Bowler J.M., Xiong J., Li J., Fox P.T. Cerebellum implicated in sensory acquisition and discrimination rather than motor control. Science. 272:1996;545-547.
27. Gibbon J., Malapani C., Dale C.L., Gallistel C.R. Toward a neurobiology of temporal cognition. Advances and challenges Curr Opin Neurobiol. 7:1997;170-184.
28. Gouzoulis-Mayfrank E., Hermle L., Kovar K.-A., Sass H. The entactogens. Ecstasy (MDMA), Eve (MDE), and other ring-substituted ethamphetamine derivatives. A novel pharmacological class among the illicit designer drugs? Nervenarzt. 67:1996;369-380.
29. Gouzoulis-Mayfrank E., Thelen B., Hermle L., Sass H. History, rationale, and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry. 31(S2):1998;63-68.
30. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar K-A, Hermle L, Spitzer M, Sass H (1999, in press): Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology.
31. Gunne L.-M. Effects of amphetamines in humans. Martin W.R. Drug Addiction II. Amphetamine, Psychotogen, and Marihuana Dependence. Handbook of Experimental Pharmacology, vol. 45/II:1977;247-275 Springer, Berlin, Heidelberg, New York.
32. Gur R.E., Resnick S.M., Gur R.C. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia. Relationship to symptom specificity Psychiatry Res. 27:1989;325-334.
33. Hermle L., Fünfgeld M., Oepen G., Botsch H., Borchardt D., Gouzoulis E., Fehrenbach R.A., Spitzer M. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects. Experimental psychosis as a tool for psychiatric research. Biol Psychiat. 32:1992;976-991.
34. Hermle L., Gouzoulis E., Oepen G., Spitzer M., Kovar K.-A., Borchardt D., Fünfgeld M., Berger M. The significance of hallucinogenic research in psychiatry. History and present Nervenarzt. 64:1993;562-571. a.
35. Hermle L., Spitzer M., Borchardt D., Kovar K.-A., Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology. 8:1993;171-176. b.
36. Kahn D.A., Prohovnik I., Lucas L.R., Sackeim H.A. Disassociated effects of amphetamine on arousal and cortical blood flow in humans. Biol Psychiat. 25:1989;755-767.
37. Kaiser H.J., Sabri O., Wagenknecht G., Lege B., Hellwig D., Buell U. A method of correlating and merging cerebral morphology and function by a special head holder. Nuklearmedizin. 33:1994;123-1261.
38. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:1987;261-276.
39. Kwapil T.R., Hegley D.C., Chapman L.J., Chapman J.P. Facilitation of word recognition by semantic priming in schizophrenia. J Abnorm Psychol. 99:1990;215-221.
40. LaBerge D. Thalamic and cortical mechanisms of attention suggested by recent positron emission tomographic experiments. J Cogn Neurosci. 2:1990;358-372.
41. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport. 6:1995;869-872.
42. Laux L., Glanzmann P., Schaffner P., Spielberger C.D. Das State-Trait-Angstinventar (STAI). 1981;Beltz, Weinheim.
43. LeDoux J.E. In search of an emotional system in the brain. Leaping from fear to emotion and consciousness Gazzaniga M.S. The Cognitive Neurosciences. 1995;1049-1061 MIT Press, Cambridge, MA.
44. Leiner H.C., Leiner A.L., Dow R.S. Cognitive and language functions of the human cerebellum. TINS. 16:1993;444-447.
45. Liddle P.F., Friston K.J., Frith C.D., Hirsch S.R., Jones T., Frackowiack R.S.J. Patterns of cerebral blood flow in schizophrenia. Br J Psychiat. 160:1992;179-186.
46. London E.D., Broussole E.P.M., Links J.M., Wong D.F., Cascella N.G., Dannals R.F., Sano M., Herning R., Snyder F.R., Rippeton L.R., Toung T.J.K., Jaffe H.J., Wagner H.N. Jr. Morphine-induced metabolic changes in human brain. Studies with positron emission tomography and [fluorine 18] fluorodeoxyglucose Arch Gen Psychiat. 47:1990;73-81. a.
47. London E.D., Cascella N.G., Wong D.F., Phillips R.L., Dannals R.F., Links J.M., Herning R., Grayson R., Jaffe J.H., Wagner H.N. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]-fluorodeoxyglucose. Arch Gen Psychiat. 47:1990;567-574. b.
48. Magaro P.A., Page J. Brain disconnection, schizophrenia, and paranoia. J Nerv Ment Dis. 171:1983;133-140.
49. Manschreck T.C., Maher B.A., Milavetz J.J., Ames D., Weisstein C.C., Schneyder M.L. Semantic priming in thought-disordered schizophrenic patients. Schizophr Res. 1:1988;61-66.
50. Mathew R.J., Wilson W.H. Substance abuse and cerebral blood flow. Am J Psychiat. 148:1991;292-305.
51. Maquet P., Dive D., Salmon E., von Frenckel R., Franck G. Reproducibility of cerebral glucose utilization measured by PET and the (18F)-2-fluoro-2-deoxy-d-glucose method in resting, healthy human subjects. Eur J Nucl Med. 16:1990;267-273.
52. Metz J.T., de Wit H., Cooper M. Amphetamine and regional cerebral metabolic rate. Effects of behavioral state and dose J Cereb Blood Flow. 11:1991;S390.
53. Murtha S., Chertkow H., Beauregard M., Dixon R., Evans A. Anticipation causes increased blood flow to the anterior cingulate cortex. Human Brain Mapping. 4:1996;103-112.
54. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class. Entactogens J Psychoact Drugs. 18:1986;305-313.
55. Oepen G., Fünfgeld M., Höll T., Zimmermann P., Landis T., Regard M. Schizophrenia - An emotional hypersensitivity of the right cerebral hemisphere. Int J Psychophysiol. 5:1987;261-264.
56. Parellada E., Catafau A.M., Bernardo M., Lomena F., Gonzalez-Monclus E., Setoain J. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients. A resting and activation SPECT study Psychiat Res Neuroimag. 55:1994;131-139.
57. Pearlson G.D., Jeffery P.J., Harris G.J., Ross C.A., Fischman M.W., Camargo E.E. Correlation of acute cocaine-induced changes in local cerebral blood flow with subjective effects. Am J Psychiat. 150:1993;495-497.
58. Pechnick R.N., Ungerleider J.T. Hallucinogens. Lowinson J.H., Ruiz P., Millman R.B., Langrod J.G. Substance Abuse. A Comprehensive Textbook. 3rd ed:1997;230-238 Williams & Wilkins, Baltimore, MD.
59. Petersen S.E., Fox P.T., Posner M.I., Mintun M., Raichle M.E. Positron emission tomographic studies of the cortical anatomy of single-word processing. Nature. 331:1988;585-589.
60. Phelps H.E., Huang S.C., Hoffmann E.J., Selin C., Sokoloff L., Kuhl D.E. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxyglucose. Validation of a method Ann Neurol. 6:1979;371-388.
61. Pietrzyk U., Herholz K., Fink G., Jacobs A., Mielke R., Slansky I., Wuerker M., Heiss W.D. An interactive technique for three-dimensional image registration. Validation for PET, SPECT, MRI, and CT brain studies J Nucl Med. 35:1994;2011-2018.
62. Reiman E.M., Lane R.D., Ahern G.L., Schwartz G.E., Davidson R.J., Friston K.J., Yun L.S., Chen K. Neuroanatomical correlates of externally and internally generated human emotion. Am J Psychiat. 154:1997;918-925.
63. Reivich M., Alavi A., Wolf A.P., Fowler J., Russell J., Arnett C., MacGregor R.R., Shiue C., Atkins H., Anand A. Glucose metabolic rate kinetic model parameter determination in man. The lumped constant and rate constants for (18-F) fluorodeoxyglucose and (11-C) deoxyglucose J Cereb Blood Flow Metab. 5:1985;179-192.
64. Rolls E.T. A theory of emotion and consciousness, and its application to understanding the neural basis of emotion. Gazzaniga M.S. The Cognitive Neurosciences. 1995;1091-1106 MIT Press, Cambridge, MA.
65. Ruoff A. Häufigkeitswörterbuch gesprochener Sprache. 2. 1990;Max Niemeyer Verlag, Auflage. Tübingen.
66. Schreckenberger M., Gouzoulis-Mayfrank E., Sabri O., Arning Ch Schulz G., Tuttass T., Wagenknecht G., Kaiser H.J., Sass H., Buell U. Cerebral interregional correlations of associative language processing. a PET activation study using 18-FDG Eur J Nucl Med. 25:1998;1511-1519.
67. Siegel B.V., Buchsbaum M.S., Bunney W.E., Gottschalk L.A., Haier R.J., Lohr J.B., Lottenberg S., Najafi A., Nuechterlein K.H., Potkin S.G., Wu J.C. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiat. 150:1993;1325-1336.
68. 15O-positron emission tomography scanning in predominantly never treated acute schizophrenics. Lancet 1983:1448-1452.
69. Sokoloff L., Reivich M., Kennedy C., Des Rosiers M.H., Patlak C.S., Pettigrew K.D., Sakurada O., Shinobara M. The C-14-deoxyglucose method for the measurement of local cerebral glucose utilization. Theory, procedure, and normal values in the conscious and anesthetized albino rat J Neurochem. 28:1977;897-916.
70. Solowji N., Hall W., Lee N. Recreational MDMA use in Sydney. A profile of "ecstasy" users and their experiences with the drug Br J Addict. 87:1992;1161-1172.
71. Spitzer M., Braun U., Hermle L., Maier S. Associative semantic network dysfunction in thought-disordered schizophrenic patients. Direct evidence from indirect semantic priming Biol Psychiat. 34:1993;864-877.
72. Spitzer M., Thimm M., Hermle L., Holzman P., Schneider F., Gouzoulis-Mayfrank E., Kischka U., Kovar K.A. Increased activation of indirect semantic associations under psilocybin. Biol Psychiat. 39:1996;1055-1057.
73. Strassman R.J., Qualls C.R., Uhlenhuth E.H., Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiat. 51:1994;98-108.
74. Szechtman H., Nahmias C., Garnett S., Firnau G., Brown G.M., Kaplan R.D., Cleghorn J.M. Effects on neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiat. 45:1988;523-532.
75. Talairach J., Tournoux P. Coplanar Stereotactic Atlas of the Human Brain. 1988;Thieme, Stuttgart.
76. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., Carpenter W.T. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiat. 49:1992;522-530.
77. Vogt B.A., Finch D.M., Olson C.R. Functional heterogeneity in cingulate cortex. The anterior executive and posterior evaluative regions Cerebr Cortex. 2:1992;435-443.
78. Vollenweider F.X., Leenders K.L., Scharfetter C., Antonini A., Maguire P., Missimer J., Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Euro Neuropsychopharm. 7:1997;9-24. a.
79. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 16:1997;357-372. b.
80. Volkow N.D., Wolf A.P., Van Gelder P., Brodie J.D., Overall J.E., Cancro R., Gomez-Mont F. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Arch Gen Psychiat. 144:1987;151-158.
81. 18F-2-Fluoro-2-deoxyglucose Psychiat Res Neuroimag. 40:1991;69-78.
82. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiat. 45:1988;609-615.
83. West E.D. Right hemisphere dysfunction and schizophrenia. Lancet. 11:1984;344.
84. Wexler B.E., Heninger G.R. Alterations in cerebral laterality during acute psychotic illness. Arch Gen Psychiat. 36:1979;278-284.
85. Wiesel F.A., Wik G., Sjögren I., Blomqvist G., Greitz T., Stone-Elander S. Regional brain glucose metabolism in drug-free schizophrenic patients and clinical correlates. Acta Psychiat Scand. 76:1987;628-641.
86. Wolkin A., Angrist B., Wolf A., Brodie J., Wolkin B., Jaeger J., Cancro R., Rotrosen J. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology. 92:1987;241-246.
87. Wolkin A., Angrist B., Wolf A., Brodie J.B., Wolkin B., Jaeger J., Cancro R., Rotrosen J. Low frontal glucose utilization in chronic schizophrenia. A replication study Am J Psychiat. 145:1988;251-253.
88. Wolkin A., Sanfilipo M., Wolf A.P., Angrist B., Brodie J.D., Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiat. 49:1992;959-965.